Biopharma Bankers: Private Equity Activity Specialty Pharma???
To all Biopharma bankers out there, can someone explain why PE firms have been very active in the spec pharma/generics space over the last 5 years or so. Covis (Cerberus and now Apollo), TerSera (GTCR), Advanz (Nordic), Arbor (KKR).
In addition, anyone has a good resource to understand the spec pharma business model in-depth? How are these companies different from typical branded pharma?
Thanks folks!
Hi Analyst5432, the silence is deafening, sorry about that.... Any of the threads below helpful?
More suggestions...
I hope those threads give you a bit more insight.
BUMP
bumping ... @privateequityfolks??
It’s not high science and there are relatively predictable cash flows along with potential for operational efficiencies / rollups. Biopharma OTOH has significant binary risk dependent on clinical trial outcomes, where good data can literally add billions to a market cap overnight, and bad data vice versa.
Quibusdam eos tempore quod minus est autem. Ea ullam rerum quod pariatur ad quasi sunt iste. Voluptas laborum aperiam quis odit voluptatum optio. Nam nihil dicta et mollitia temporibus perspiciatis.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...